In order to participate in this study, you must be able to speak and read Dutch fluently.
The goal of this study is to evaluate how safe and effective the new drug E2814 is in combination with Lecanemab for the treatment of participants with a genetic variant of Alzheimer’s disease. You need to know whether you have this genetic variant beforehand, we ask you to show documentation stating this beforehand. To participate in this research, it is not necessary to have an Alzheimer’s diagnosis or symptoms. However, it is possible to participate in this research if you have Alzheimer’s or matching symptoms. The study compares the effect of the new drug E2814 with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’) in combination with the anti-amyloid treatment Lecanemab. The study drug and Lecanemab are administered through an intravenous (IV) infusion.

It is thought that Alzheimer’s disease is caused by certain proteins (beta-amyloid and tau) that accumulate in the brain. These accumulations cause the brain to stop working properly, and a person develops memory problems, for example. Recent research showed that accumulation of the protein tau can begin as early as 10-15 years before the first memory problems. It is hoped that the drug E2814 can slow down the accumulation of tau and the progression of Alzheimer’s disease.

You and your study partner, someone who knows you well and can answer questions about your daily functioning, will have approximately 105 to 182 study visits, during approximately 4 to 7 years. The duration of a visit is not always the same because not every visit has the same procedures. Some of these visits may last 1 hour, others 3 hours or longer. The research takes place in Amsterdam or at
your home.